Recursion announces clinical trial approvals for REC-3565 and REC-4539, targeting B-cell malignancies and small-cell lung cancer. Recursion announced that the UK Medicines and Healthcare Products ...

Whenever machine learning is applied to a given field of industry, defining the objective is one of the most salient questions. Just what are you trying to find out? In the biological sciences, that ...

Unmet clinical needs often serve as the fundamental driving force behind drug discovery programs. During lead discovery, an intensive search ensues to find a drug-like small molecule or biological ...

Recursion Pharmaceuticals just acquired a pair of AI-related biotechs. This could bolster its drug discovery capabilities and better help its clients. But the stock is high-risk and requires a ...

Recursion has stumbled through an early test of its tech-enabled approach to drug discovery, reporting a hit on its phase 2 primary endpoint of safety and tolerability but failing to wow on the ...

SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...

This is a preview. Log in through your library . Abstract Taking Chomsky's Syntactic Structures as a starting point, this paper explores the use of recursive techniques in contemporary linguistic ...

AI for drug development is very fashionable in biotech, and for good reason. 23andMe's consumer business could one day provide a bedrock of stability. Recursion Pharmaceutical's research services ...

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...